TPTF is a technology-driven venture capital fund, investing in innovative companies shaping the future of global business.

Innovation-driven investment partner

Our Mission

We are an innovation-driven, added value investment partner

The Trans-Pacific Technology Fund (TPTF) is a technology-driven venture capital fund, investing in innovative companies shaping the future of global business. We work actively with the leadership of our portfolio companies from different regions of the world, supporting their growth.
Read More
The Trans-Pacific Technology Fund (TPTF) is a technology-driven venture capital fund, investing in innovative companies shaping the future of global business. We work actively with the leadership of our portfolio companies from different regions of the world, supporting their growth.
The cornerstone of every great company is great people

Our Approach

The cornerstone of every great company is great people

At TPTF, we believe the cornerstone of every great company is great people. Before a fascinating innovation can become a game-changing company on a global scale, we believe there needs to be daring entrepreneurs to convert the concept into reality. In addition to providing capital, we consider ourselves a committed partner, supporting our entrepreneurs via our extensive international resources, deep domain expertise and, most importantly, our passion to work together to build great companies.
Read More
At TPTF, we believe the cornerstone of every great company is great people. Before a fascinating innovation can become a game-changing company on a global scale, we believe there needs to be daring entrepreneurs to convert the concept into reality. In addition to providing capital, we consider ourselves a committed partner, supporting our entrepreneurs via our extensive international resources, deep domain expertise and, most importantly, our passion to work together to build great companies.
Innovation that change the world

Our Focus Area

Innovations that change the world

We invest in disruptive, platform technologies focusing on the sectors where we have leading domain expertise, including but not limited to: advanced materials, health/life sciences, ICT, IOT and robotics/automation. We have a multi-stage investment strategy to work with companies ranging from early to expansion/late stage. Through our extensive network of collaborative partners around the world, we have a global investment scope, seeking to invest in companies across Asia, North America and Europe.
Read More
We invest in disruptive, platform technologies focusing on the sectors where we have leading domain expertise, including but not limited to: advanced materials, health/life sciences, ICT, IOT and robotics/automation. We have a multi-stage investment strategy to work with companies ranging from early to expansion/late stage. Through our extensive network of collaborative partners around the world, we have a global investment scope, seeking to invest in companies across Asia, North America and Europe.

About Us

At TPTF we believe the cornerstone of every great company is great people

The Trans-Pacific Technology Fund (TPTF) is a technology-driven venture capital fund, investing in innovation companies shaping the future of global business. We work actively with the leadership of our portfolio companies from different region of the world, supporting their growth. At TPTF we believe the cornerstone of every great company is great people. Through our extensive network of collaborative partners around the world, we have a global investment scope, seeking to invest in companies across Asia, North America and Europe.

Our Partners

We are partnering with the most reputable research powerhouses worldwide and other honored but private investors

Our Portfolio

Apexigen
APEXIGEN is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer.
Finch
FINCH THERAPEUTICS is a late clinical-stage company focused on developing therapeutics leveraging its Full-Spectrum Microbiota (FSM) and Selected Microbiota (RSM) platform. The Company is initially targeting recurrent C. difficile, ulcerative colitis and an autism spectrum disorder.
Quanergy
QUANERGY SYSTEMS INC. is an award-winning smart sensing solution company based in Silicon Valley. The Company is a leading provider of LiDAR sensors and perception software for real-time capture and processing of 3D data and object detection, identification, classification and tracking. Quanergy’s solutions are applicable in numerous sectors including transportation, security, industrial automation, 3D mapping, mining, agriculture, drones, robotics, and smart cities.
CleanWave
CLEANWAVE TECHNOLOGIES combines patented and proprietary technology in electric motors, power electronics, and software controls, along with world-class design and state-of-the-art manufacturing, to produce drive systems that are significantly higher performance, but at the same time more cost-effective than any other competing systems in the world.
Googol Tech
GOOGOL TECHNOLOGY is a leading company specializing in smart manufacturing, robotics, and industrial IoT. The Company offers control systems, industrial IoT/cloud and AI/ML manufacturing data services for advanced machinery, industrial robots, and smart factories.
Kata.ai
KATA provides the leading AI platform that is initially targeting the Bahasa language in Indonesia with the strategy to expand into other countries and languages in SE Asia. The platform, Kata.ai, is an omni-channel conversational commerce engine using Human Assisted Artificial Intelligence technology for brands & commerce providers. The AI platform is based on Natural Language Understanding technology to automate conversation and provides solutions based on customer behavioral data.

Our Portfolio

Heal
HEAL is a digital healthcare company directly delivering primary care and other high-value healthcare services via contracts with major insurance companies, corporations, and directly to patients, leveraging the Company’s proprietary AI and data analytics platform.
Rancher
RANCHER Labs builds open-source container management software that makes it easier for enterprises to deploy and manage distributed applications in any organization, running on any infrastructure.
Weiche
WEICHE is a vertical eco-enterprise, having built an extensive platform focusing on maximizing transportation efficiency and economics.
Zymergen
ZYMERGEN is a bioinformatics and engineering company which integrates proprietary automation, machine learning algorithms, and the world’s largest database of bioreachable molecules and microbial genomes. The Company accelerates discovery and development of novel products in agriculture, chemicals, materials, pharmaceuticals, electronics and personal care sectors.
Megapro Biomedical
MEGAPRO BIOMEDICAL develops its proprietary magnetic resonance imaging (MRI) contrast agent and the first non-sugar based intravenous (IV) iron for treating the iron-deficiency anemia with less side effects and higher potency.
Applied Biocode
Applied BioCode (ABC) is a Taiwan biotechnology company that is engaged in designing, developing and manufacturing in-vitro and protein testing products focusing on molecular infectious disease. ABC currently distributes patented, micrometer scaled Barcode Magnetic Beads (BMB) in conjunction with a digital multiplexing molecular platform, that detects pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections.
CrownBio
Crown Bioscience is a platform technology company providing drug discovery and development services in the areas of Oncology, Inflammation, and Metabolic Diseases. Leveraging the best-in-class Patient-Derived Xerographic (PDX) platform help clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services. They are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan. Crown Bioscience was acquired by the JSR Corporation in 2018.
See More

Our Team

Screenshot 2021-05-06 at 06.26.01

Managing Partner

Glenn Kline

Glenn is a Managing Partner of TPTF and also serves as the President & CEO of 360ip. He has over 30 years of experience investing in high technology companies, fund management, technology/IP commercialization and working with high technology growth companies. Prior to co-founding 360ip, Glenn was a General Partner at Battelle Ventures/Innovation Valley Partners. He earned his MBA from UCLA and BA from Pomona College.
Herb-Lin

Managing Partner

Herb Lin

Herb Lin is a Managing Partner of TPTF and served as the President of ITIC, having extensive experience in venture capital and in high-tech industry. He worked for Intel for over 12 years in the U.S., Taipei and China with responsibilities in design and application engineering, processor design, manufacturing, and later heading the product and technical marketing team for the Asia-Pacific region.
Barry_Lee

Investment Professional

Barry Lee

Barry has ~15 years of experience in venture capital fund management and technology investments. Prior to joining TPTF and 360ip, he served as an Investment Manager at China Development Industrial Bank (CDIB) and Partners, focusing on fund management and investments. He has also worked in various capacities with top international companies including business development, direct investment/M&A, and finance. Barry received his MBA from the Marshall School of Business at the University of Southern California and his BS in Biotechnology from the University of Pennsylvania.
KENJI YAMAMOTO

Investment Professional

Kenji Yamamoto

Kenji is a Principal in TPTF. Kenji has ~10 years of experience in investments across Asia and Africa. Prior to joining TPTF and 360ip, Kenji served as Deputy General Manager of the investment division for an international mining/materials company based in Hong Kong. Prior to that position, Kenji worked at KPMG in various capacities, including in the M&A Advisory Group. He started his career at as a co-founder and of a startup in Japan leading sales & marketing and finance functions. Kenji earned his MBA from INSEAD and his BS degree from the University of Tokyo.
SARAH CHIU

Investment Professional

Sarah Chiu

Sarah serves as Finance Director. Prior to joining TPTF, Sarah served as Finance Controller for several large, multinational organizations, including Optoma Corporation and Dentsu, Young & Rubicam, Inc. She began her career as an accounting professional by working at two of the Big Four accounting firms in Taiwan as a registered CPA serving international clients, such as Intel, Oracle, Omron and WPP PLC. Sarah then served as a Project Manager at the Taiwan Futures Exchange (TAIFEX).
Bruce Han

Investment Professional

Bruce Han

Bruce has over 10 years of industry experience in semiconductor industry, currently serves as Principal in TPTF. He is responsible for investment evaluation, due diligence and other venture operational activities. Prior to joining TPTF, Bruce worked for United Microelectronics Corporation (UMC) specializing in IC foundry-related engineering, quality assurance, customer service, and business management. Bruce earned his M.S. and B.A. from National Cheng Kung University.
JIM LI

Investment Professional

Jim Li

Jim is a Principal in TPTF, focusing on the evaluation and investment in high tech companies. Prior to joining TPTF, he held various hardware/software engineering positions in Symbol Technologies and Telxon Corporation, Silicon Graphics and Innomedia Inc. Jim also has had experience as an entrepreneur, having co-founded IC Media Corporation in the CMOS image sensor business and served as director, VP, EVP, and CTO positions (the company was later acquired by MagnaChip).
Ben _Chou

Investment Professional

Ben Chou

Ben Chou is a Managing Director at TPTF. Ben has approximately 20 years of venture capital industry experience, particularly focusing on cross-border investments between Silicon Valley, Hong Kong, China and Taiwan. Ben’s core investment sectors include green technology, cloud computing, hardware components and bio-medical industries. Ben holds a M.S. in Management Information Systems from Boston University, and a B.S. in Computer Science from National Chiao-Tung University.
LIZZIE LEE

Investment Professional

Lizzie Lee

Lizzie is Principal in TPTF. She invests at the intersection of healthcare, device, technology, and data. She is passionate about the discovery of new drug approaches, digitalization of healthcare, genomics, innovative medical instruments, synthetic biology, personalized nutrition, and other deep sciences. Prior to joining TPTF, Lizzie was an investment professional at Sinopac Venture Capital and Singapore family office fund Enspire Capital, where she sourced and led multiple early stage technology investments across Silicon Valley, China, and Taiwan.
ALEX YANG

Venture Partner

Alex Yang

Alex has more than 10 years of investment experience across North America and the Greater China region. Prior to joining TPTF as a Venture Partner, he served as a Principal for a merchant bank focused on tech and consumer investments for a consortium of family offices and institutional investors. Alex has also worked in various capacities with McKinsey & Co., Silver Lake Partners, CDH Funds, and CDIB across New York, San Francisco, Hong Kong, and Taipei. Alex received a BS in Finance from Wharton Business School and a BA in Arts & Sciences from the University of Pennsylvania.
BOH SOON

Venture Partner

Boh Soon Lim

Boh Soon has more than 30 years of investment and technology experience. Prior to joining TPTF as Venture Parter, Boh Soon was the CEO of the Kuwait Finance House in Singapore, the CEO of Vietcombank Fund Management Company in Vietnam — where he established several investment funds — and served in various senior management positions at UBS Capital Asia, Singapore Technologies Group and Rothschild Ventures Asia. Boh Soon received his M.S. and Ph.D. degrees from the University of Strathclyde. He is a Fellow of the Singapore Institute of Directors, and is currently an Independent Director on the board of 5 publicly-listed companies in Singapore, Malaysia and Hong Kong.
MIKE

Venture Partner

Mike Tung

Mike has more than 18 years of investment experience across Greater China and the United States having held various positions with Bank of America, HSBC, Morgan Stanley, and UBS. Mike is currently a Partner at Oski Capital Group and also the Managing Partner at Red Sails Investments, a diversified venture capital and private equity partnership. Mike earned a B.A. in Psychology with a minor in Chinese from the University of California, Davis in 2001 and has a MSc in Global Finance from NYU Stern School of Business and the Hong Kong University of Science and Technology.
VOLKER

Venture Partner

Volker Heistermann

Volker brings 23 years of hands-on investment and innovation management experience in Germany, the US and across Asia. Prior to joining TPTF as Venture Partner, Volker has worked with multinational corporations such as Google, Audi, AT&T, Commerzbank, and Rutberg & Co. In 2010, Mr. Heistermann co-founded Yushan Ventures, Inc. The firm’s extended portfolio includes investments in Twilio, Ethereum and Zephyrus Biosciences and has resulted in six exits. Volker earned his B.A. in Financial Law from the University of Bielefeld (Germany) and an International Marketing from the University of California, Berkeley. He is also an Advisor to APEC and a member of the Dedicated Short-Range Communication (DSRC) – SEA Work Group.
Nitin Gupta

Venture Partner

Nitin Gupta

Nitin is an accomplished private equity and investment banking professional with 18+ years of experience. He has underwritten multiple structured finance and private equity transactions in various sectors including IT, Telecom and Media. Prior to TPTF, he was the regional head of IIML Fund Managers Pte Ltd in Singapore, focusing on investments in the ASEAN region primarily Malaysia, Indonesia and Vietnam. Nitin is a Chartered Accountant and has received his MBA from the National University of Singapore.
Spencer Karrington -- 2021 Picture (B&W)

Analyst

Spencer Karrington

Spencer Karrington is an Analyst at TPTF participating in due diligence and researching potential investment opportunities, focusing on digital health, medical and biotech companies in the United States and Southeast Asia. Previously, Spencer interned at TPTF and was also the Founder & President of the St. Andrews Venture Capital Club. He is completing his International Political Economy Honours degree at the University of St. Andrews.

Screenshot 2021-05-06 at 06.20.34

Analyst

Kevin Lin

Kevin is an Analyst at TPTF responsible for conducting research in hardware and software related startups, providing reports in industries such as LiDAR, blockchain, and HPC, and participating in due diligence of multiple companies. Prior to TPTF, he was a deep learning engineer at NVIDIA, developing solutions and conducting research for perception systems in autonomous vehicles. He also had experience in designing software libraries for NVIDIA GPU, bridging the gap between hardware and software developers. Kevin earned a B.S. in Electrical Engineering and Computer Science from University of California, Berkeley.

David_S

Analyst

David Erskine

David is an Analyst at TPTF. Before joining, David was the Head of Deals for the St Andrews Venture Capital Club. Furthermore, he was a finalist for the 2020 Thomas Blake Glover Scholarship, which provided him the opportunity to research Japanese Equities and AI. David has earned an M.A. in Philosophy graduating with First-Class Honours from the University of St Andrews.

Contact Us

Send us a message for any inquiries regarding TPTF
12F, No.149, Xinyi Rd Sec.3,
Da-an District, Taipei City,
Taiwan
1 Chome-4-1 Nihonbashimuromachi, Chuo City, Tokyo 103-8001,
Japan
Contact Us
© 2020 Trans-Pacific Technology. Fund All Rights Reserved.